The initial success of Viagra undeniably reshaped the pharmaceutical landscape, but betting in companies strongly reliant on off-patent versions presents a challenging picture. Although early earnings were significant, the cessation of patents and the emergence of less expensive alternatives have eroded the customer base. Thus, a thorough analysis